Home » Posts tagged with » Switzerland
Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech

Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech

Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the use of the BNT162b2 Covid-19 vaccine from US pharma giant Pfizer and German biotech company BioNTech. The Swiss pharma regulator said that as per the data it has assessed, the level of protection afforded seven days following the second dose of the mRNA vaccine is […]

Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn

German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]

Continue reading …
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial

Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients with episodic migraine (EM). The results of the mid-stage trial – NCT01952574 are being presented by the Swiss drugmaker at the 18th Migraine Trust Virtual Symposium. The five-year, open-label treatment […]

Continue reading …
Nestlé to fully own Aimmune Therapeutics through $2bn deal

Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected to help the Swiss conglomerate’s subsidiary Nestlé Health Science and Aimmune Therapeutics to create a global leader in the prevention […]

Continue reading …
Novartis bags Kesimpta FDA approval for relapsing forms of MS

Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) for the treatment of relapsing forms of multiple sclerosis (RMS). The approval is for the use of the anti-CD20 monoclonal antibody (mAb) as a subcutaneous injection in clinically isolated syndrome, […]

Continue reading …
Northway Biotechpharma to manufacture Memo’s Covid1-9 drug MTX-COVAB

Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the latter will manufacture the former’s MTX-COVAB – a COVID-19 antibody candidate in a four-month fast-track process. Northway Biotechpharma is a biopharmaceutical contract development and manufacturing organization (CDMO) based in Lithuania. MTX-COVAB, which is the lead antibody candidate […]

Continue reading …
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]

Continue reading …
Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The transaction is expected to help Roche advance the development of its nanopore sequencer through the access to Sequencing by Expansion (SBX), Stratos Genomics’ unique chemistry. Roche said that once developed, […]

Continue reading …
Construction begins on Merck Biotech Development Center in Switzerland

Merck has broken ground on the €250 million Merck Biotech Development Center, a new biotech development facility in Switzerland at Corsier-sur-Vevey. The new facility will be used for biotech development and manufacturing for clinical studies. Construction on the biotech development facility is likely to be wrapped up next year with full operations to begin by […]

Continue reading …
ForaCare Suisse launches FOR A 6 GTel diabetes monitoring device

ForaCare Suisse has launched a new cellular multi-functional diabetes monitoring device FORA 6 GTel based on its Lab in the Pocket technology. The Lab in the Pocket technology, which has also been newly launched, is available on the GTel model and FOR A 6 Series products, said the Swiss healthcare technology company. According to ForaCare […]

Continue reading …
Page 1 of 3123